Automation of cell manufacturing with the CliniMACS Prodigy®

Listen to Dr. Andrew Kaiser explaining the evolving role of automation

  • Why do you need to automate your manufacturing process?
  • What are your options for automation platforms?
  • When should you start thinking about automation? 

Podcast: The evolving role of automation

In this podcast interview, Dr. Andrew Kaiser discusses how the approach to automation changes throughout development and commercialization of a cell therapy, using CAR T cell therapy as an example.

Andrew Kaiser, Ph.D., is a Senior R&D Project Manager at Miltenyi Biotec. His team develops tools and technologies for clinical applications of adoptive cell therapy with a focus on automation of gene-modified T cell manufacturing. Dr. Kaiser obtained his Ph.D. working on translational research of dendritic cell maturation for vaccines at IDM Pharma and the Cochin Institute in Paris, France. As a post-doc at the Surgery Branch of the NCL, Bethesda, USA and the Netherlands Cancer Institute in Amsterdam, he investigated gene-modified T cells for cancer immunotherapy. Dr. Kaiser is the scientific coordinator of CARAT, a Horizon 2020 European consortium that aims to deliver innovative cell manufacturing tools and technologies to facilitate the safe, automated, and cost-effective manufacture of personalized cancer treatment options.

A PDF transcript of the podcast is available under DOI: 10.18609/cgti.2017.070

Citation: Cell Gene Therapy Insights 2017; 3(8), 677-681.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Related information